Core Scientific reached a deal with an activist on February 18, 2026. The company disclosed the cooperation agreement with Two Seas Capital LP in an 8-K/A filed the following day, and the terms are specific enough to matter.

Three independent directors. Staged appointments. One current director shown the door at the 2027 annual meeting. That is a meaningful governance restructuring, not a routine board refresh.

The Appointment Schedule Puts Pressure on Management Now

The first director must be seated before March 15, 2026, which means the clock was already running at the time of the filing. The second director arrives at or shortly after the 2026 annual meeting, no later than September 15, 2026. The third follows before the 2027 annual meeting. Each appointment happens in consultation with Two Seas, which gives the investor real input at every stage rather than a one-time concession.

The sequencing matters because it prevents Core Scientific from satisfying the agreement with a single friendly appointment and then stalling. Two Seas locked in three distinct windows with hard deadlines.

Two Seas Gave Up Leverage to Get Certainty

In exchange, Two Seas accepted customary standstill provisions for one year following execution and voting commitments running through the 2027 annual meeting. That is the trade: guaranteed board representation in exchange for a cap on escalation.

Standstill agreements typically prohibit the investor from acquiring additional shares above a threshold, running a proxy contest, or publicly agitating during the standstill period. Two Seas gave up those tools for a year. The voting commitment means it cannot vote against management on most matters through 2027. For a company with $CORZ's Bitcoin miner and hosting profile, where capital allocation decisions around power contracts and fleet expansion carry real weight, having Three Seas-nominated directors in the room during those decisions is the actual prize.

One Director Out Changes the Composition Math

The agreement specifies that one current director will not be nominated for re-election at the 2027 annual meeting. That clause converts the board expansion from additive to substitutive over time. By 2027, the board will have three new independent directors nominated in consultation with Two Seas and one fewer incumbent. The net governance shift is larger than a simple headcount addition.

$CORZ's Filing Risk Score sits at 100, reflecting the density of material event disclosures the company has generated. The elevated disclosure cadence here is the cooperation agreement itself, which triggered both Item 1.01 and Item 5.02 in the same filing. Event Momentum is also at the ceiling, driven by the volume and severity of recent filings. The BTC Exposure Score of 80 anchors the company firmly in the Bitcoin miner category, where board composition decisions feed directly into how management approaches power procurement, hosting contracts, and capital deployment.

What the Stock Has Done While Governance Shifted

$CORZ has gained roughly 17% over the past month and about 59% year to date through May 20, 2026, with the stock trading above its 20-day, 50-day, and 200-day moving averages. The 52-week high of $25.17 was set on May 14, 2026. That price trajectory does not make the governance story less relevant. Activist cooperation agreements often surface when an investor sees a gap between operational potential and current management execution, and the stock's recovery from a 52-week low of $9.77 in May 2025 suggests the gap was real.

The cooperation agreement was filed February 19. The stock's subsequent move through the spring happened with this governance structure already in place.

The First Appointment Is the Immediate Test

The March 15, 2026 deadline for the first director appointment was the earliest concrete deliverable under the agreement. Whether Core Scientific met that deadline on time, and who was appointed, determines whether the cooperation agreement is being executed in good faith or managed for delay. A subsequent 8-K disclosing the director appointment and any Form 4 or proxy amendment naming the new board member would confirm compliance. If that filing has not appeared, the deadline has passed and the agreement is already under pressure.

Research only. Not investment advice.